Selecting targeted therapies based on biomarkers in individual tumor specimens led to improved outcomes for chemotherapy-refractory lung cancer patients in a prospective phase II clinical trial that promises to be a landmark in developing personalized medicine for lung cancer.Disease control rates ranged from zero to 100% in five biomarker-based groups of patients, depending on how well a particular drug corresponded with a group's molecular features, lead researcher Dr. Edward S. Kim reported April...